Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 12/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PRKDC | P78527 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 4/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093302 | 0.80 | ATR (0.44) | KCNH2ATRPTGS2PRKDCATM | |
| SCHEMBL29802559 | 0.80 | KCNH2 (0.55) | KCNH2PTGS2PTGS1 | |
| SCHEMBL23093464 | 0.80 | KCNH2 (0.55) | KCNH2PTGS2PTGS1 | |
| SCHEMBL15306535 | 0.79 | KCNH2 (0.48) | KCNH2ATRPTGS2PTGS1PRKDC | |
| SCHEMBL15308507 | 0.78 | KCNH2 (0.60) | KCNH2ATRPRKDCATM | |
| SCHEMBL23093261 | 0.75 | PTGS2 (0.47) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL3094683 | 0.74 | CDK5 (0.52) | KCNH2ATRPTGS2PTGS1PRKDC | |
| SCHEMBL7209645 | 0.72 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL9420134 | 0.71 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL3754393 | 0.71 | PTGS2 (0.46) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BOARD INSTITUTE, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | PTGES2, PTGS2, PTGES | KCNH2 3964/4885ATR 4804/4885PTGS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.